Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,494.14 -7.51 -0.05%
S&P 500 1,878.34 2.95 0.16%
NASDAQ 4,137.82 10.85 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,171.08 -4.89 -0.15%
FTSE 100 6,684.33 9.59 0.14%
DAX 9,483.95 -60.24 -0.63%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Edwards Lifesciences Corporation



  Law Offices of Howard G. Smith Announces Investigation on Behalf of
  Investors of Edwards Lifesciences Corporation

Business Wire

BENSALEM, Pa. -- September 25, 2013

Law Offices of Howard G. Smith announces that it is investigating potential
claims on behalf of purchasers of the common stock of Edwards Lifesciences
Corporation (“Edwards Lifesciences” or the “Company”) (NYSE:EW) concerning
possible violations of federal securities laws. The investigation focuses on
certain statements issued by the Company between April 25, 2012 and April 23,
2013.

Edwards Lifesciences is a medical device maker that designs and markets
artificial heart valves, among other things, including valves that require
traditional open-chest surgery and a newer “SAPIEN” line of transcatheter
heart valves that may be implanted using a minimally invasive procedure.

The investigation is related to allegations that the Company issued false
and/or misleading statements and failed to disclose material facts related to
the prospects, projected sales and adoption of the Company’s Edwards SAPIEN
transcatheter aortic heart valve, including allegations that adoption of
SAPIEN was weaker than the Company claimed, due to concerns among physicians
over the risks and complexity of the procedure for implanting the valve.

On April 23, 2013, the Company disclosed that approximately 20 candidate
hospitals had postponed SAPIEN training, that there was substantially no
backlog of patients awaiting SAPIEN implants, and that the Company’s financial
results had been and would likely continue to be weaker than estimates.
Following this news, Edwards Lifesciences’ stock price fell nearly 22% on
April 24, 2013, on extremely heavy trading volume.

If you purchased Edwards Lifesciences shares, if you have information or would
like to learn more about these claims, or if you have any questions concerning
this announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at
(215) 638-4847, Toll Free at (888) 638-4847, or by email to
howardsmith@howardsmithlaw.com, or visit our website at
www.howardsmithlaw.com.

Contact:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement